{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:24:54Z","timestamp":1785252294180,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human milk contains more than 150 different oligosaccharides, which together are among to the quantitatively predominant solid components of breast milk. The oligosaccharide content and composition of human milk show large inter-individual differences. Oligosaccharide content is mostly influenced by genetic variants of the mother\u2019s secretor status. Oligosaccharides in human milk are utilized by infants\u2019 intestinal bacteria, affecting bacterial composition and metabolic activity. Maternal secretor status, and respective differing fucosylated oligosaccharide content, has been associated both with reduced and increased risk of infection in different populations of breastfed infants, possibly due to environmental conditions and the infant\u2019s genotype. There are no safety concerns regarding the addition of previously approved oligosaccharides to infant formula; however, no firm conclusions can be drawn about clinically relevant benefits either. Therefore, infant formulas with synthetic oligosaccharide additives are currently not preferentially recommended over infant formulas without such additives. We consider the use of terms such as \u201chuman milk oligosaccharides\u201d and corresponding abbreviations such as \u201cHMO\u201d in any advertising of infant formula to be an inappropriate idealization of infant formula. Manufacturers should stop this practice, and such marketing practices should be prevented by responsible supervisory authorities. Pediatricians should inform families that infant formulas supplemented with synthetic oligosaccharides do not resemble the complex oligosaccharide composition of human milk.<\/jats:p>","DOI":"10.1186\/s40348-022-00146-y","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T18:04:41Z","timestamp":1657735481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Infant formulas with synthetic oligosaccharides and respective marketing practices: Position Statement of the German Society for Child and Adolescent Medicine e.V. (DGKJ), Commission for Nutrition"],"prefix":"10.1186","volume":"9","author":[{"given":"Christoph","family":"B\u00fchrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Ensenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jochum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Kalhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Koletzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Lawrenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Mihatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Posovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rudloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"146_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/glycob\/cws074","volume":"22","author":"L Bode","year":"2012","unstructured":"Bode L (2012) Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22:1147\u20131162. https:\/\/doi.org\/10.1093\/glycob\/cws074","journal-title":"Glycobiology"},{"key":"146_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s00112-014-3292-5","volume":"163","author":"S Rudloff","year":"2015","unstructured":"Rudloff S, Kunz C (2015) Oligosaccharide in Frauenmilch. Monatsschr Kinderheilkd 163:790\u2013795. https:\/\/doi.org\/10.1007\/s00112-014-3292-5","journal-title":"Monatsschr Kinderheilkd"},{"key":"146_CR3","doi-asserted-by":"publisher","unstructured":"Asadpoor M, Peeters C, Henricks PAJ et al. (2020) Anti-pathogenic functions of non-digestible oligosaccharides in vitro. Nutrients 12.https:\/\/doi.org\/10.3390\/nu12061789","DOI":"10.3390\/nu12061789"},{"key":"146_CR4","doi-asserted-by":"publisher","first-page":"SE51","DOI":"10.4052\/tigg.1734.1SE","volume":"30","author":"T Urashima","year":"2018","unstructured":"Urashima T, Hirabayashi J, Sato S et al (2018) Human milk oligosaccharides as essential tools for basic and application studies on galectins. Trends Glycosci Glycotechnol 30:SE51\u2013SE65. https:\/\/doi.org\/10.4052\/tigg.1734.1SE","journal-title":"Trends Glycosci Glycotechnol"},{"key":"146_CR5","doi-asserted-by":"publisher","first-page":"456S","DOI":"10.3945\/an.111.001529","volume":"3","author":"PA Prieto","year":"2012","unstructured":"Prieto PA (2012) Profiles of human milk oligosaccharides and production of some human milk oligosaccharides in transgenic animals. Adv Nutr 3:456S-S464. https:\/\/doi.org\/10.3945\/an.111.001529","journal-title":"Adv Nutr"},{"key":"146_CR6","doi-asserted-by":"publisher","first-page":"574459","DOI":"10.3389\/fnut.2020.574459","volume":"7","author":"G Lefebvre","year":"2020","unstructured":"Lefebvre G, Shevlyakova M, Charpagne A et al (2020) Time of lactation and maternal fucosyltransferase genetic polymorphisms determine the variability in human milk oligosaccharides. Front Nutr 7:574459. https:\/\/doi.org\/10.3389\/fnut.2020.574459","journal-title":"Front Nutr"},{"key":"146_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/MPG.0000000000001402","volume":"64","author":"C Kunz","year":"2017","unstructured":"Kunz C, Meyer C, Collado MC et al (2017) Influence of gestational age, secretor, and Lewis blood group status on the oligosaccharide content of human milk. J Pediatr Gastroenterol Nutr 64:789\u2013798. https:\/\/doi.org\/10.1097\/MPG.0000000000001402","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"146_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3945\/ajcn.116.139980","volume":"105","author":"MK McGuire","year":"2017","unstructured":"McGuire MK, Meehan CL, McGuire MA et al (2017) What\u2019s normal? Oligosaccharide concentrations and profiles in milk produced by healthy women vary geographically. Am J Clin Nutr 105:1086\u20131100. https:\/\/doi.org\/10.3945\/ajcn.116.139980","journal-title":"Am J Clin Nutr"},{"key":"146_CR9","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/cid\/ciu633","volume":"59","author":"J Nordgren","year":"2014","unstructured":"Nordgren J, Sharma S, Bucardo F et al (2014) Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. Clin Infect Dis 59:1567\u20131573. https:\/\/doi.org\/10.1093\/cid\/ciu633","journal-title":"Clin Infect Dis"},{"key":"146_CR10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/jamapediatrics.2015.2002","volume":"169","author":"DC Payne","year":"2015","unstructured":"Payne DC, Currier RL, Staat MA et al (2015) Epidemiologic association between FUT2 secretor status and severe rotavirus gastroenteritis in children in the United States. JAMA Pediatr 169:1040\u20131045. https:\/\/doi.org\/10.1001\/jamapediatrics.2015.2002","journal-title":"JAMA Pediatr"},{"key":"146_CR11","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1038\/s41467-018-07476-4","volume":"9","author":"S Ramani","year":"2018","unstructured":"Ramani S, Stewart CJ, Laucirica DR et al (2018) Human milk oligosaccharides, milk microbiome and infant gut microbiome modulate neonatal rotavirus infection. Nat Commun 9:5010. https:\/\/doi.org\/10.1038\/s41467-018-07476-4","journal-title":"Nat Commun"},{"key":"146_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.43","volume":"5","author":"NJ Andreas","year":"2016","unstructured":"Andreas NJ, Al-Khalidi A, Jaiteh M et al (2016) Role of human milk oligosaccharides in group B Streptococcus colonisation. Clin Transl Immunology 5. https:\/\/doi.org\/10.1038\/cti.2016.43","journal-title":"Clin Transl Immunology"},{"key":"146_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jpeds.2004.04.054","volume":"145","author":"AL Morrow","year":"2004","unstructured":"Morrow AL, Ruiz-Palacios GM, Altaye M et al (2004) Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr 145:297\u2013303. https:\/\/doi.org\/10.1016\/j.jpeds.2004.04.054","journal-title":"J Pediatr"},{"key":"146_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/bfm.2006.1.207","volume":"1","author":"MBF Stepans","year":"2006","unstructured":"Stepans MBF, Wilhelm SL, Hertzog M et al (2006) Early consumption of human milk oligosaccharides is inversely related to subsequent risk of respiratory and enteric disease in infants. Breastfeed Med 1:207\u2013215. https:\/\/doi.org\/10.1089\/bfm.2006.1.207","journal-title":"Breastfeed Med"},{"key":"146_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/infdis\/jiz072","volume":"220","author":"JM Colston","year":"2019","unstructured":"Colston JM, Francois R, Pisanic N et al (2019) Effects of child and maternal histo-blood group antigen status on symptomatic and asymptomatic enteric infections in early childhood. J Infect Dis 220:151\u2013162. https:\/\/doi.org\/10.1093\/infdis\/jiz072","journal-title":"J Infect Dis"},{"key":"146_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/INF.0000000000003014","volume":"40","author":"D Muthumuni","year":"2021","unstructured":"Muthumuni D, Miliku K, Wade KH et al (2021) Enhanced protection against diarrhea among breastfed infants of nonsecretor mothers. Pediatr Infect Dis J 40:260\u2013263. https:\/\/doi.org\/10.1097\/INF.0000000000003014","journal-title":"Pediatr Infect Dis J"},{"key":"146_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fped.2019.00297","volume":"7","author":"MW Larsson","year":"2019","unstructured":"Larsson MW, Lind MV, Laursen RP et al (2019) Human milk oligosaccharide composition is associated with excessive weight gain during exclusive breastfeeding-an explorative study. Front Pediatr 7:297. https:\/\/doi.org\/10.3389\/fped.2019.00297","journal-title":"Front Pediatr"},{"key":"146_CR18","doi-asserted-by":"publisher","unstructured":"Sakanaka M, Gotoh A, Yoshida K et al. (2019) Varied pathways of infant gut-associated bifidobacterium to assimilate human milk oligosaccharides: prevalence of the gene set and its correlation with bifidobacteria-rich microbiota formation. Nutrients 12https:\/\/doi.org\/10.3390\/nu12010071","DOI":"10.3390\/nu12010071"},{"key":"146_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s10620-020-06092-x","volume":"65","author":"EC Davis","year":"2020","unstructured":"Davis EC, Dinsmoor AM, Wang M et al (2020) Microbiome composition in pediatric populations from birth to adolescence: impact of diet and prebiotic and probiotic interventions. Dig Dis Sci 65:706\u2013722. https:\/\/doi.org\/10.1007\/s10620-020-06092-x","journal-title":"Dig Dis Sci"},{"key":"146_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1021\/acsinfecdis.7b00064","volume":"3","author":"DL Ackerman","year":"2017","unstructured":"Ackerman DL, Doster RS, Weitkamp J-H et al (2017) Human milk oligosaccharides exhibit antimicrobial and antibiofilm properties against group B Streptococcus. ACS Infect Dis 3:595\u2013605. https:\/\/doi.org\/10.1021\/acsinfecdis.7b00064","journal-title":"ACS Infect Dis"},{"key":"146_CR21","doi-asserted-by":"publisher","unstructured":"Cheng L, Akkerman R, Kong C et al. (2020) More than sugar in the milk: human milk oligosaccharides as essential bioactive molecules in breast milk and current insight in beneficial effects. Crit Rev Food Sci Nutr:1\u201317. https:\/\/doi.org\/10.1080\/10408398.2020.1754756.","DOI":"10.1080\/10408398.2020.1754756"},{"key":"146_CR22","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/gutjnl-2016-312819","volume":"67","author":"CA Autran","year":"2018","unstructured":"Autran CA, Kellman BP, Kim JH et al (2018) Human milk oligosaccharide composition predicts risk of necrotising enterocolitis in preterm infants. Gut 67:1064\u20131070. https:\/\/doi.org\/10.1136\/gutjnl-2016-312819","journal-title":"Gut"},{"key":"146_CR23","doi-asserted-by":"publisher","unstructured":"Wejryd E, Mart\u00ed M, Marchini G et al. (2018) Low diversity of human milk oligosaccharides is associated with necrotising enterocolitis in extremely low birth weight infants. Nutrients 10https:\/\/doi.org\/10.3390\/nu10101556","DOI":"10.3390\/nu10101556"},{"key":"146_CR24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3945\/jn.113.187799","volume":"144","author":"E van Niekerk","year":"2014","unstructured":"van Niekerk E, Autran CA, Nel DG et al (2014) Human milk oligosaccharides differ between HIV-infected and HIV-uninfected mothers and are related to necrotizing enterocolitis incidence in their preterm very-low-birth-weight infants. J Nutr 144:1227\u20131233. https:\/\/doi.org\/10.3945\/jn.113.187799","journal-title":"J Nutr"},{"key":"146_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322771","author":"AC Masi","year":"2020","unstructured":"Masi AC, Embleton ND, Lamb CA et al (2020) Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2020-322771","journal-title":"Gut"},{"key":"146_CR26","doi-asserted-by":"publisher","first-page":"CD002971","DOI":"10.1002\/14651858.CD002971.pub5","volume":"7","author":"M Quigley","year":"2019","unstructured":"Quigley M, Embleton ND, McGuire W (2019) Formula versus donor breast milk for feeding preterm or low birth weight infants. Cochrane Database Syst Rev 7:CD002971. https:\/\/doi.org\/10.1002\/14651858.CD002971.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"146_CR27","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.3945\/jn.116.236919","volume":"146","author":"KC Goehring","year":"2016","unstructured":"Goehring KC, Marriage BJ, Oliver JS et al (2016) Similar to those who are breastfed, infants fed a formula containing 2'-fucosyllactose have lower inflammatory cytokines in a randomized controlled trial. J Nutr 146:2559\u20132566. https:\/\/doi.org\/10.3945\/jn.116.236919","journal-title":"J Nutr"},{"key":"146_CR28","doi-asserted-by":"publisher","first-page":"e0166070","DOI":"10.1371\/journal.pone.0166070","volume":"11","author":"E Vazquez","year":"2016","unstructured":"Vazquez E, Barranco A, Ramirez M et al (2016) Dietary 2'-fucosyllactose enhances operant conditioning and long-term potentiation via gut-brain communication through the vagus nerve in rodents. PLoS ONE 11:e0166070. https:\/\/doi.org\/10.1371\/journal.pone.0166070","journal-title":"PLoS ONE"},{"key":"146_CR29","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3389\/fnins.2020.00770","volume":"14","author":"SA Fleming","year":"2020","unstructured":"Fleming SA, Mudd AT, Hauser J et al (2020) Human and bovine milk oligosaccharides elicit improved recognition memory concurrent with alterations in regional brain volumes and hippocampal mRNA expression. Front Neurosci 14:770. https:\/\/doi.org\/10.3389\/fnins.2020.00770","journal-title":"Front Neurosci"},{"key":"146_CR30","unstructured":"European-Commission (2016). Commission Delegated Regulation (EU) 2016\/127 of 25 September 2015 supplementing Regulation (EU) No 609\/2013 of the European Parliament and of the Council as regards the specific compositional and information requirements for infant formula and follow-on formula and as regards requirements on information relating to infant and young child feeding. Off J Eur Union: L 25\/21\/1\u201329."},{"key":"146_CR31","doi-asserted-by":"publisher","first-page":"13469","DOI":"10.1021\/acs.jafc.0c03766","volume":"68","author":"SS van Leeuwen","year":"2020","unstructured":"van Leeuwen SS, Te Poele EM, Chatziioannou AC et al (2020) Goat milk oligosaccharides: their diversity, quantity, and functional properties in comparison to human milk oligosaccharides. J Agric Food Chem 68:13469\u201313485. https:\/\/doi.org\/10.1021\/acs.jafc.0c03766","journal-title":"J Agric Food Chem"},{"key":"146_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.copbio.2013.01.008","volume":"24","author":"D Barile","year":"2013","unstructured":"Barile D, Rastall RA (2013) Human milk and related oligosaccharides as prebiotics. Curr Opin Biotechnol 24:214\u2013219. https:\/\/doi.org\/10.1016\/j.copbio.2013.01.008","journal-title":"Curr Opin Biotechnol"},{"key":"146_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.aca.2017.12.036","volume":"1010","author":"S Austin","year":"2018","unstructured":"Austin S, B\u00e9net T (2018) Quantitative determination of non-lactose milk oligosaccharides. Anal Chim Acta 1010:86\u201396. https:\/\/doi.org\/10.1016\/j.aca.2017.12.036","journal-title":"Anal Chim Acta"},{"key":"146_CR34","doi-asserted-by":"publisher","unstructured":"Eussen SRBM, Mank M, Kottler R et al. (2021) Presence and levels of galactosyllactoses and other oligosaccharides in human milk and their variation during lactation and according to maternal phenotype. Nutrients. 13https:\/\/doi.org\/10.3390\/nu13072324","DOI":"10.3390\/nu13072324"},{"key":"146_CR35","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.2903\/j.efsa.2014.3760","volume":"12","author":"EFSA-Panel-on-Dietetic-Products","year":"2014","unstructured":"EFSA-Panel-on-Dietetic-Products (2014) Scientific opinion on the essential composition of infant and follow-on formulae. EFS2 12:3760. https:\/\/doi.org\/10.2903\/j.efsa.2014.3760","journal-title":"EFS2"},{"key":"146_CR36","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1017\/S0007114518000120","volume":"119","author":"A Sk\u00f3rka","year":"2018","unstructured":"Sk\u00f3rka A, Pie\u015bcik-Lech M, Ko\u0142odziej M et al (2018) Infant formulae supplemented with prebiotics: are they better than unsupplemented formulae? An updated systematic review. Br J Nutr 119:810\u2013825. https:\/\/doi.org\/10.1017\/S0007114518000120","journal-title":"Br J Nutr"},{"key":"146_CR37","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.2903\/j.efsa.2011.2222","volume":"9","author":"EFSA","year":"2011","unstructured":"EFSA (2011) Scientific opinion on the substantiation of health claims related to fructo-oligosaccharides (FOS) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 781) pursuant to Article 13(1) of Regulation (EC) No 1924\/2006. EFSA J 9:2222","journal-title":"EFSA J"},{"key":"146_CR38","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.2903\/j.efsa.2011.2060","volume":"9","author":"EFSA","year":"2011","unstructured":"EFSA (2011) Scientific opinion on the substantiation of health claims related to galacto oligosaccharides (GOS) and reduction of gastro intestinal discomfort (ID 763) and decreasing potentially pathogenic microorganisms (ID 765) pursuant to Article 13(1) of Regulation (EC) No 1924\/2006. EFSA J 9:2060","journal-title":"EFSA J"},{"key":"146_CR39","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/nutrit\/nuw025","volume":"74","author":"L Bode","year":"2016","unstructured":"Bode L, Contractor N, Barile D et al (2016) Overcoming the limited availability of human milk oligosaccharides: challenges and opportunities for research and application. Nutr Rev 74:635\u2013644. https:\/\/doi.org\/10.1093\/nutrit\/nuw025","journal-title":"Nutr Rev"},{"key":"146_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jbiotec.2017.07.030","volume":"258","author":"GA Sprenger","year":"2017","unstructured":"Sprenger GA, Baumg\u00e4rtner F, Albermann C (2017) Production of human milk oligosaccharides by enzymatic and whole-cell microbial biotransformations. J Biotechnol 258:79\u201391. https:\/\/doi.org\/10.1016\/j.jbiotec.2017.07.030","journal-title":"J Biotechnol"},{"key":"146_CR41","doi-asserted-by":"publisher","unstructured":"EFSA (2015) Safety of 2\u2032-O-fucosyllactose as a novel food ingredient pursuant to Regulation (EC) No 258\/97. EFS2 13. https:\/\/doi.org\/10.2903\/j.efsa.2015.4184","DOI":"10.2903\/j.efsa.2015.4184"},{"key":"146_CR42","doi-asserted-by":"publisher","unstructured":"EFSA (2015) Safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258\/97. EFS2 13. https:\/\/doi.org\/10.2903\/j.efsa.2015.4183","DOI":"10.2903\/j.efsa.2015.4183"},{"key":"146_CR43","doi-asserted-by":"publisher","first-page":"e05717","DOI":"10.2903\/j.efsa.2019.5717","volume":"17","author":"D Turck","year":"2019","unstructured":"Turck D, Castenmiller J, de Henauw S et al (2019) Safety of 2'-fucosyllactose\/difucosyllactose mixture as a novel food pursuant to Regulation (EU) 2015\/2283. EFS2. 17:e05717. https:\/\/doi.org\/10.2903\/j.efsa.2019.5717","journal-title":"EFS2."},{"key":"146_CR44","doi-asserted-by":"publisher","first-page":"e05907","DOI":"10.2903\/j.efsa.2019.5907","volume":"17","author":"D Turck","year":"2019","unstructured":"Turck D, Castenmiller J, de Henauw S et al (2019) Safety of lacto-N-tetraose (LNT) as a novel food pursuant to Regulation (EU) 2015\/2283. EFS2 17:e05907. https:\/\/doi.org\/10.2903\/j.efsa.2019.5907","journal-title":"EFS2"},{"key":"146_CR45","doi-asserted-by":"publisher","unstructured":"Turck D, Castenmiller J, Henauw S de et al. (2020) Safety of 3\u2019-sialyllactose (3\u2019-SL) sodium salt as a novel food pursuant to Regulation (EU) 2015\/2283. EFS2 18. https:\/\/doi.org\/10.2903\/j.efsa.2020.6098","DOI":"10.2903\/j.efsa.2020.6098"},{"key":"146_CR46","doi-asserted-by":"publisher","unstructured":"Turck D, Castenmiller J, Henauw S de et al. (2020) Safety of 6\u2032-sialyllactose (6\u2032-SL) sodium salt as a novel food pursuant to Regulation (EU) 2015\/2283. EFS2 18. https:\/\/doi.org\/10.2903\/j.efsa.2020.6097","DOI":"10.2903\/j.efsa.2020.6097"},{"key":"146_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/MPG.0000000000000889","volume":"61","author":"BJ Marriage","year":"2015","unstructured":"Marriage BJ, Buck RH, Goehring KC et al (2015) Infants fed a lower calorie formula with 2'FL show growth and 2'FL uptake like breast-fed infants. J Pediatr Gastroenterol Nutr 61:649\u2013658. https:\/\/doi.org\/10.1097\/MPG.0000000000000889","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"146_CR48","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/MPG.0000000000001520","volume":"64","author":"G Puccio","year":"2017","unstructured":"Puccio G, Alliet P, Cajozzo C et al (2017) Effects of infant formula with human milk oligosaccharides on growth and morbidity: a randomized multicenter trial. J Pediatr Gastroenterol Nutr 64:624\u2013631. https:\/\/doi.org\/10.1097\/MPG.0000000000001520","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"146_CR49","doi-asserted-by":"publisher","unstructured":"Berger B, Porta N, Foata F et al. (2020) Linking human milk oligosaccharides, infant fecal community types, and later risk to require antibiotics. mBio 11. https:\/\/doi.org\/10.1128\/mBio.03196-19","DOI":"10.1128\/mBio.03196-19"},{"key":"146_CR50","doi-asserted-by":"publisher","first-page":"2333794X1983399","DOI":"10.1177\/2333794X19833995","volume":"6","author":"HM Storm","year":"2019","unstructured":"Storm HM, Shepard J, Czerkies LM et al (2019) 2'-Fucosyllactose is well tolerated in a 100% whey, partially hydrolyzed infant formula with Bifidobacterium lactis: a randomized controlled trial. Glob Pediatr Health 6:2333794X19833995. https:\/\/doi.org\/10.1177\/2333794X19833995","journal-title":"Glob Pediatr Health"},{"key":"146_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000490306","volume":"90","author":"L Bode","year":"2019","unstructured":"Bode L (2019) Human milk oligosaccharides: next-generation functions and questions. Nestle Nutr Inst Workshop Ser 90:191\u2013201. https:\/\/doi.org\/10.1159\/000490306","journal-title":"Nestle Nutr Inst Workshop Ser"},{"key":"146_CR52","first-page":"29","volume":"091","author":"E Kommission","year":"1999","unstructured":"Kommission E (1999) RICHTLINIE 1999\/21\/EG DER KOMMISSION vom 25. M\u00e4rz 1999 \u00fcber di\u00e4tetische Lebensmittel f\u00fcr besondere medizinische Zwecke. Amtsblatt der Europ\u00e4ischen Kommission L 091:29\u201336","journal-title":"Amtsblatt der Europ\u00e4ischen Kommission L"},{"key":"146_CR53","unstructured":"Bundesministerium der Justiz und f\u00fcr Verbraucherschutz (2017) Verordnung \u00fcber di\u00e4tetische Lebensmittel (Di\u00e4tverordnung). https:\/\/www.gesetze-im-internet.de\/di_tv\/BJNR004150963.html."}],"updated-by":[{"DOI":"10.1186\/s40348-022-00147-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000}}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-022-00146-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-022-00146-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-022-00146-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T06:03:39Z","timestamp":1658556219000},"score":1,"resource":{"primary":{"URL":"https:\/\/molcellped.springeropen.com\/articles\/10.1186\/s40348-022-00146-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1186\/s40348-022-00146-y","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"11 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40348-022-00147-x","URL":"https:\/\/doi.org\/10.1186\/s40348-022-00147-x","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C. B\u00fchrer acted as a consultant\/expert for public courts. He was a member of the scientific advisory boards at the Fresenius, the WIdO, and the IQTIG. CB received fees from the Chiesi and Nestl\u00e9 for lectures and training courses. The BMBF supported his research projects with third-party funds.R. Ensenauer receives an expense allowance for her work for the Thieme Publishers Pediatrics Up2Date. The BMBF, the Innovation Fund of the G-BA, the DFG, and the foundations Sternstunden e.V., Willi-Althof-Stiftung, EKFS, and Stiftung Kardiovaskul\u00e4re Pr\u00e4vention LMU M\u00fcnchen supported RE\u2019s research projects with third-party funds.F. Jochum is consultant\/expert for the DKG and the G-BA, from which he receives contributions. His employer has carried out contract research with the department of Pediatric Nutrition Research on different aspects of infant formulae for Fonterra, Humana, Nestl\u00e9 and Hipp. They took place under the leadership of FJ. FJ is a member of the advisory board of the Nestl\u00e9 Nutrition Institute. He received fees for giving lectures at the intensive care training DHZB, the Med. Hochschule Brandenburg, and the University Greifswald. He has also authored\/co-authored several publications focusing on clinical nutrition or treatment of pediatric patients including neonates. He conducted research projects focusing on the nutrition of newborns, for which he received a fee as well as compensations for travel expenses. FJ owns two patents relating to newborns.H. Kalhoff received fees from the Duleve Mederau and Stallergenes for giving lectures and training courses.B. Koletzko served as a consultant for the German Research Foundation in the grant review board for\u00a0clinical trials. He received remunerations for educational and review activities and travel cost reimbursement\u00a0from Annenberg, Barilla,\u00a0Bayer, Cogitando, Cheplapharm, Danone, DGC,\u00a0DSM, Hipp, Nestle, and Reckitt and the nonprofit organization Family\u00a0Larsson Rosenquist Foundation. He was a member of the scientific advisory boards of the Family Larsson Rosenquist Foundation and the Task Force on Dietary Fat Quality of the International Union of Nutritional Sciences. He is author\/co-author and editor for the Karger Publishers, Springer Publishers, and Thieme Publishers. His employer received support for scientific and educational\u00a0project from the European Commission, the European Research Council, the German Research Council, the German Federal Government, the Government of Bavaria, the US National Institutes of Health, the Ministry of Primary Industries, New Zealand, the Else Kr\u00f6ner Fresenius Foundation, the Larsson Rosenquist Foundation, the University of Amsterdam, and the companies Danone, DGC, Hipp, and Nestle. The employer of BK holds the rights of two patents filed by BK concerning a method for fatty acid analysis and for a device for collecting buccal cell samples.B. Lawrenz receives fees for his consulting\/expert work for the GSK, KVWL Consult GmbH, MSD, Pfizer, and Sanofi. He also works in advisory boards for the GSK, MSD, Pfizer, and Sanofi, from which he receives contributions. He took on paid lectures\/training courses for the BVKJ, the BVKJ Service GmbH, GSK, KVWL Consult Life Science, MSD, RG, and Sanofi. He is an author\/co-author for the Hansisches Verlagskontor and the Marseille Publishers.W. A. Mihatsch received contributions for his work in the scientific advisory boards for the human milk research and feeding Prize Committee of the company Nutricia. He has given lectures and training courses for the \u00d6GKJ, DGPE, GNPI, ESPGHAN, ESPR, and DGKJ. He conducts research projects and clinical studies for the Gie\u00dfen University, University of Madrid, Ulm University, and the University of Applies Sciences Neu Ulm and gives lectures on breastfeeding encouragement.C. Posovszky acted as a consultant\/expert for the Nestl\u00e9 Health Science GmbH, Germany, from which he received a fee. He worked in the scientific advisory boards of the Shire Austria and Shire Deutschland GmbH, Takeda (Switzerland), Nutricia Milupa, and Pharmacosmos and received contributions from them. CP received monetary contributions for giving lectures\/training courses for the AbbVie Deutschland GmbH, Nutricia GmbH, Nutricia Milupa SA, Takeda (Switzerland), Gebro Pharma GmbH Austria, Publicare AG, and FomF GmbH. The Shire International GmbH and FresuCare AG support CP\u2019s research projects with third-party funds.S. Rudloff received fees for her lectures\/training courses for the DGKJ, HIPP, Nutricia, and the Heiner-Brunner-Seminar of the GPGE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}